Ligand Pharmaceuticals received a rating increase and price target raise from Bank of America on August 5, while the company also listed its stock on Nasdaq.
1 report, 1 independent
Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ligand Pharmaceuticals received a rating increase and price target raise from Bank of America on August 5, while the company also listed its stock on Nasdaq.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ligand Pharmaceuticals
biopharmaceutical company based out of La Jolla, California
Nothing else this week.
-
Bank of America
American multinational banking and financial services corporation
Related events
- Bank of America analysts raised price targets for several U.S. industrial and healthcare stocks in July 2025.
- Bank of America raised its target price on Morgan Stanley shares, while TD Cowen assumed coverage and MarketBeat reported analyst ratings.
- Amphenol received multiple analyst upgrades and target price increases from firms including Citigroup, Bank of America, and Jefferies Financial Group on July 9, 2026.
- Ally Financial saw changes in its stock target price and average rating from major financial firms.
- Morgan Stanley and Bank of America raised price targets on NetApp shares, with MarketBeat reporting the consensus rating.